RepliCel Life Sciences
RepliCel Life Sciences engages in developing hair follicle cell replication technology for patients suffering from androgenetic alopecia. Learn more
Launch date
Employees
Market cap
€2.4m
Enterprise valuation
€2m (Public information from Jul 2024)
Share price
CAD0.055 RP.V
North Vancouver British Columbia (HQ)
Authorizing premium user...